Toxicology Testing Sample Clauses

Toxicology Testing. The School may, on a random basis and when deemed appropriate and pertinent, perform breathalyser and/or toxicology tests on any student or group of students. Such tests will be performed by taking a saliva, urine and/or hair sample. In the event that
AutoNDA by SimpleDocs
Toxicology Testing. If recommended by the PHC, the Member shall enroll in a professional, vetted toxicology testing program that will provide random testing of breath or biological specimens, results of which will be sent to the Treating Provider and the Member. The selected toxicology testing program shall use an approved laboratory with an established chain of custody for samples. Screening will be for appropriate substances of abuse, prescribed and non-prescribed medications or narcotic antagonists. If necessary, duplicate samples and witnessed sample screening will also occur. If the Member has a positive test, it is the Member’s responsibility to notify the PHC immediately. The Treating Provider will also immediately alert the PHC. In addition, the Member shall refrain from energy drinks, herbal supplements, mouthwash, poppy seeds or any other type of substance that may inadvertently cause false positives on drug screens.
Toxicology Testing. Physician shall enroll in a professional toxicology testing program that will provide random bodily fluid testing the results of which will be sent to the Treating Provider and Physician. The selected toxicology-testing program shall use an approved laboratory with an established chain of custody for samples. Screening will be for appropriate drugs of abuse or narcotic antagonist. If necessary, duplicate samples and witnessed sample screening will also occur. If Physician has a positive test, it is the Physician’s responsibility to notify the Committee immediately. In addition, Physician shall refrain from energy drinks or herbal supplements as these may inadvertently cause false positives on drug screens.
Toxicology Testing. I agree to abstain from any and all mood-altering chemicals (including but not limited to alcohol, marijuana, tranquilizers, sedatives, stimulants, narcotics, ultram (tramadol), nubain, antidepressants, and soporifics, androgenic steroids, scheduled and/or unscheduled drugs, mood altering over-the-counter medications, etc.) except as prescribed by my physician and only after consultation with the WELLNESS PROGRAM. I also agree that I will not consume poppy seeds and I will not consume ethyl alcohol in any form (alcohol “free” wine or beer, mouthwash, cough syrup, in food, communion wine or in any other form). If any mood altering and/or potentially addictive medications are required I will notify the WELLNESS PROGRAM, in advance if possible, and provide documentation of the need for the medication (i.e. copy of the prescription or note from the prescribing physician) within 3 days. If the need for the medication is ongoing, I will renew verification every 90 days. (Initials)
Toxicology Testing. Physician shall enroll in a professional toxicology testing program that will provide random bodily fluid testing the results of which will be sent to the treating provider and Physician. The selected toxicology testing program shall use an approved laboratory with an established chain of custody for samples. Screening will be for appropriate drugs of abuse or narcotic antagonist. If necessary, duplicate samples and witnessed sample screening will also occur.
Toxicology Testing. I agree to abstain at all times during the term of this agreement from any and all potentially addictive chemicals whether over-the-counter, scheduled or unscheduled (including but not limited to alcohol (ie ethyl alcohol or ethanol), marijuana, tranquilizers, sedatives, stimulants, narcotics, opioids including ultram (tramadol), nubain, soporifics, androgenic steroids, or any other known addictive drug) except as prescribed by my physician and only after consultation with APHP. If any mood altering and/or potentially addictive medications are required or recommended by my physician I will notify APHP, in advance if possible, and provide documentation of the need for the medication (i.e. note from the prescribing physician) within 3 days. If the need for the medication is ongoing, I will renew verification every 90 days. I also agree to avoid exposure to anything that will cause my urine drug test to be positive. In that regard I will avoid such items as “hemp oil” “coca tea” and I will not consume poppy seeds (which can be found in xxxxx sauces, breads, salad dressings, and in or on other foods). I will not use ethyl alcohol in any form (including alcohol “free” wine or beer, over-the-counter drugs containing alcohol (cough syrup, Nyquil or other similar OTC drugs or supplements), mouthwash or other hygiene products containing ethanol, foods containing ethanol (desserts, vanilla extract, etc), communion wine, sanitizing hand or body gels (Purell or other), or any other form of ethyl alcohol). Intentional use of any of these products or medications without a physicians order is a violation of this agreement. (Initials)

Related to Toxicology Testing

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • ODUF Testing 6.6.1 Upon request from TWTC, AT&T shall send ODUF test files to TWTC. The Parties agree to review and discuss the ODUF file content and/or format. For testing of usage results, AT&T shall request that TWTC set up a production (live) file. The live test may consist of TWTC’s employees making test calls for the types of services TWTC requests on ODUF. These test calls are logged by TWTC, and the logs are provided to AT&T. These logs will be used to verify the files. Testing will be completed within thirty (30) days from the date on which the initial test file was sent.

  • Testing Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant’s use. Tenant shall be required to pay the cost of such annual test of the Premises; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant’s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this Section 30, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord’s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.

  • Stability Testing Patheon shall conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees specified in Schedule C. Patheon shall not make any changes to these testing protocols without prior written approval from the Client. In the event that any batch of Products fails stability testing, Patheon and the Client shall jointly determine the proceedings and methods to be undertaken to investigate the causes of such failure, including which party shall bear the cost of such investigation, provided that Patheon shall not be liable for any such costs unless there has been a failure by it to provide the Manufacturing Services in accordance with the Specifications and cGMPs. Patheon will provide any and all data and results relating to the stability testing upon request by the Client.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!